Glomeria Therapeutics
Develops and commercialises medical devices to treat nephropathy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€2.8m | Grant | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 3031 % | 71 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (170959 %) | (10016 %) | 335 % |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (193934 %) | (40242 %) | (387 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Glomeria Therapeutics, founded in 2010, is a clinical-stage company headquartered in Chieti, Italy, specializing in the development of medical devices and therapies for patients with severe nephropathy and cardiopathy. The company operates in the medical device sector with a focus on peritoneal dialysis, a home-based treatment that offers greater clinical efficacy and lifestyle flexibility compared to hemodialysis. Glomeria Therapeutics targets its products toward healthcare providers and patients managing chronic kidney diseases.
The company's product portfolio includes the SmartPD, an automated system for managing the instillation of peritoneal dialysis solutions, and DesmoPD, a connection system designed to enhance security for patients undergoing peritoneal dialysis. Additionally, Glomeria develops buffered peritoneal dialysis solutions, such as Glucothera (lactate-buffered) and Alkathera (bicarbonate-buffered), to support these treatments. The business model centers on the research, development, and commercialization of these hospital products and medical therapy devices. Since its inception, the firm has secured approximately $1.13 million in funding over three rounds, with its first round in September 2015. A significant grant of $3.29 million was awarded on September 30, 2018, with investors including the European Union, EIC Fund, Sofimac Investment Managers, and Spindial.
Glomeria Therapeutics aims to address the needs of patients with serious nephrological diseases by creating a structure that minimizes infrastructure costs while maximizing access to biomedical research and scientific knowledge. This approach enables medical professionals to effectively treat conditions such as peritoneal dialysis, chronic renal failure, hemodialysis, and hemofiltration. The company's focus remains on providing solutions that improve the quality of life for individuals with severe kidney and heart-related conditions.
Keywords: peritoneal dialysis, nephropathy treatment, cardiopathy devices, chronic kidney disease, home dialysis, medical devices, SmartPD system, DesmoPD connector, Glucothera, Alkathera, renal failure therapy, hemodialysis alternatives, automated dialysis, dialysis solutions, kidney disease treatment, cardiac patient care, medical therapy devices, clinical-stage company, nephrology, cardiology